Brokerages Set Hologic, Inc. (NASDAQ:HOLX) PT at $78.00

Key Points

• Hologic, Inc. has received a consensus recommendation of "Moderate Buy" from 17 brokerages, with an average 1-year price target of $78.00.
• The company recently reported quarterly earnings of $1.08 EPS, exceeding estimates, and achieved revenue of $1.02 billion, reflecting a 1.2% increase year-over-year.
• Institutional investors continue to show strong interest, with 94.73% of the stock owned by hedge funds and other institutional investors, indicating robust investor confidence.

Shares of Hologic, Inc. (NASDAQ:HOLX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the seventeen analysts that are covering the firm, MarketBeat reports. Eight equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $78.00.

Several analysts recently commented on HOLX shares. Stephens dropped their price objective on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. Mizuho set a $75.00 price objective on Hologic in a research note on Thursday, July 31st. Morgan Stanley upped their target price on shares of Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. UBS Group upped their target price on shares of Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a research note on Thursday, July 31st. Finally, Argus raised shares of Hologic from a "hold" rating to a "buy" rating and set a $80.00 target price for the company in a research note on Monday, August 18th.

Hedge Funds Weigh In On Hologic

Hedge funds have recently made changes to their positions in the business. Kovitz Investment Group Partners LLC bought a new position in Hologic in the fourth quarter valued at $264,000. Northern Trust Corp boosted its stake in shares of Hologic by 26.9% during the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock worth $226,898,000 after buying an additional 668,086 shares during the last quarter. Schonfeld Strategic Advisors LLC boosted its stake in shares of Hologic by 48.9% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 27,220 shares of the medical equipment provider's stock worth $1,962,000 after buying an additional 8,945 shares during the last quarter. Comerica Bank boosted its stake in shares of Hologic by 2.9% during the 4th quarter. Comerica Bank now owns 106,649 shares of the medical equipment provider's stock worth $7,688,000 after buying an additional 3,010 shares during the last quarter. Finally, Freestone Grove Partners LP acquired a new position in shares of Hologic during the 4th quarter worth about $17,787,000. 94.73% of the stock is owned by institutional investors.

Hologic Trading Up 0.8%

Shares of HOLX stock traded up $0.50 on Friday, hitting $67.12. The stock had a trading volume of 1,080,191 shares, compared to its average volume of 1,721,362. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. Hologic has a twelve month low of $51.90 and a twelve month high of $84.39. The company has a fifty day moving average price of $66.15 and a two-hundred day moving average price of $62.50. The firm has a market cap of $14.93 billion, a P/E ratio of 27.85, a PEG ratio of 2.44 and a beta of 0.49.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping the consensus estimate of $1.05 by $0.03. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm's revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, analysts forecast that Hologic will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.